Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA II: FDA, Industry Reach Tentative 'Alignment' On ANDA Review Issues

This article was originally published in The Pink Sheet Daily

Executive Summary

Negotiations to renew user fee program continue as finance issues remain unresolved.

You may also be interested in...

Generic User Fee Talks Reach 'Final Wording' But Still Not Done

FDA and industry say they have reached tentative agreement, but finance subgroup says more discussion needed.

GDUFA Negotiations Shift To 'Tiered' Fee Models

Finance subgroup talks about new structure for generic drug user fee program that could mean bigger firms would pay more.

ANDA User Fees Offer Sponsor Relief, But More Facility Pain

Final GDUFA I application fees decrease amid expected boost in submissions, while facility fees will increase for the fourth time in five years.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts